Advertisement
ALLR vs NRXP
Which Stock Would AI Choose? Allarity Therapeutics (ALLR) vs. NRx Pharmaceuticals (NRXP) Stock Comparison
Key Takeaways
- ALLR and NRXP are both clinical-stage biopharmaceutical companies, yet they operate in distinct niches: precision oncology versus neuropsychiatry (central nervous system, or CNS, conditions).
- NRXP carries a materially larger market capitalization and an imminent regulatory catalyst, while ALLR is a micro-cap focused on a single lead drug candidate.
- Analyst sentiment is notably more constructive on NRXP, which holds a Strong Buy consensus, versus a single maintained Buy rating for ALLR.
- Both names carry the elevated clinical, financing, and dilution risk typical of pre-revenue biotechs, making their relative performance highly catalyst-dependent.
- Tickeron AI Verdict: NRXP — favored on catalyst density, balance-sheet positioning, and broader pipeline diversification.
- For deeper context on each name, explore ALLR Major News and ALLR Today's Price Move, plus NRXP Major News and NRXP Today's Price Move.
- To see how automated strategies currently rank these and other names, explore Trending AI Robots.
Introduction
Investors comparing ALLR (Allarity Therapeutics) and NRXP (NRx Pharmaceuticals) are essentially weighing two very different clinical-stage bets within healthcare. Allarity is a precision-medicine play centered on a single oncology asset, while NRx is building a broader neuropsychiatry platform with several regulatory catalysts on the horizon. This comparison may appeal to traders tracking catalyst-driven price moves as well as longer-horizon investors evaluating risk-reward profiles across early-stage drug developers. Both stocks are speculative and thinly capitalized, so their stock comparison hinges less on current earnings and more on pipeline progress, regulatory milestones, and financing durability.
ALLR Overview and Recent Performance
Allarity Therapeutics (ALLR) is a Phase 2 clinical-stage precision-medicine company developing stenoparib, a dual inhibitor of PARP (poly-ADP-ribose polymerase) and the WNT pathway, for advanced ovarian cancer. Its differentiating feature is a proprietary Drug Response Predictor (DRP) companion-diagnostic platform designed to identify patients most likely to respond. In recent market activity, the stock has traded near the low end of its 52-week range with a market capitalization in the low tens of millions of dollars, reflecting the financing pressures common to micro-cap biotechs. Recent weeks have brought a first commercial agreement under its newly established CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory services strategy, an expansion of in-house lab capabilities, and a $20 million non-convertible debt facility intended to extend its cash runway. Earlier FDA (U.S. Food and Drug Administration) Fast Track designation for stenoparib in advanced ovarian cancer remains a notable prior catalyst, and a single analyst maintains a Buy rating with a double-digit price target.
NRXP Overview and Recent Performance
NRx Pharmaceuticals (NRXP) is a clinical-stage biopharmaceutical company focused on neuropsychiatry, anchored by a portfolio of ketamine-based and depression therapies. Its lead near-term opportunity is KETAFREE, a preservative-free ketamine product under FDA review via an ANDA (Abbreviated New Drug Application), with a GDUFA (Generic Drug User Fee Amendments) goal date that has kept the stock in focus. The company is also advancing NRX-100 toward an NDA (New Drug Application), and NRX-101 in partnership with the military through an $11 million DARPA (Defense Advanced Research Projects Agency) prime contract for treatment-resistant depression. Recent weeks have seen manufacturing process validation and a labeling review letter for preservative-free ketamine, alongside expansion of its HOPE Therapeutics clinic network and the GeNeuro acquisition targeting ALS (amyotrophic lateral sclerosis). Analyst coverage remains Strong Buy with price targets well above the current share price.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection of AI trading bots from a much larger universe of automated strategies. While Tickeron offers hundreds of AI Trading Bots that collectively trade thousands of different tickers, only the strategies best suited to current market conditions earn a place in this curated section. Each bot operates with its own trading style, strategy, timeframe, performance history, and the specific set of tickers it trades, so no two approaches are identical. This breadth allows users to browse bots ranging from short-term momentum systems to longer-horizon trend-following models, each backed by measurable statistics. For traders seeking data-driven perspective on names like ALLR and NRXP, exploring the Trending AI Robots page can provide a useful layer of automated market analysis.
Head-to-Head Comparison
The core contrast between these two stocks is breadth versus concentration. NRXP operates a multi-asset pipeline spanning ketamine commercialization, depression therapies, an interventional psychiatry clinic network, and an ALS program, supported in part by non-dilutive government funding. ALLR, by contrast, is effectively a single-asset story centered on stenoparib, with its DRP diagnostic platform as a secondary value driver. On financial positioning, NRXP holds a larger cash balance and market capitalization, while Allarity's small size and debt facility elevate dilution and liquidity risk. Growth drivers differ sharply: NRXP's momentum is tied to an imminent regulatory decision and government partnerships, whereas Allarity's hinges on clinical data and companion-diagnostic adoption. Sector exposure also diverges, with NRXP levered to CNS/psychiatry demand and Allarity to oncology. Overall, market sentiment and analyst coverage currently lean more favorably toward NRXP's near-term catalyst stack.
Tickeron AI Verdict
Based on observable factors such as catalyst density, balance-sheet positioning, pipeline diversification, and relative analyst sentiment, Tickeron's AI would likely favor NRXP over ALLR in the current environment. NRXP presents a nearer-term regulatory event, multiple parallel development tracks, and non-dilutive funding sources that may support more consistent trend behavior. Allarity's concentrated, single-asset profile and micro-cap financing structure introduce comparatively greater instability. This assessment is probabilistic rather than definitive, reflecting relative positioning between two speculative, catalyst-driven equities rather than a recommendation on either security.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLR is a Hold and NRXP is a Hold.
ALLR's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for ALLR moved out of overbought territory on November 04, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 instances where the indicator moved out of the overbought zone. In 14 of the 14 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLR as a result. In 64 of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
ALLR moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ALLR moved below the 200-day moving average on October 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALLR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALLR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ALLR just turned positive on October 21, 2026. Looking at past instances where ALLR's MACD turned positive, the stock continued to rise in 25 of 31 cases over the following month. The odds of a continued upward trend are 81%.
Following a +29.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLR advanced for three days, in 144 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.361) is normal, around the industry mean (3.498). P/E Ratio (-1.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NRXP in +14.75% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NRXP advanced for three days, in 191 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NRXP's RSI Indicator exited the oversold zone, 32 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where NRXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for NRXP just turned positive on November 06, 2026. Looking at past instances where NRXP's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXP as a result. In 74 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for NRXP moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NRXP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-606.141) is very low in comparison to the industry average of (3.498). P/E Ratio (-4.667) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NRXP | ||
|---|---|---|
OUTLOOK RATING 1..100 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 75 | |
P/E GROWTH RATING 1..100 | 11 | |
SEASONALITY SCORE 1..100 | 19 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ALLR | NRXP | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 9 days ago 82% | 8 days ago 82% |
| Declines ODDS (%) | 2 days ago 90% | 10 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALLR’s FA Score shows that 0 FA rating(s) are green while NRXP’s FA Score has 2 green FA rating(s).
- ALLR’s FA Score: 0 green, 5 red.
- NRXP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALLR’s TA Score shows that 3 TA indicator(s) are bullish while NRXP’s TA Score has 5 bullish TA indicator(s).
- ALLR’s TA Score: 3 bullish, 7 bearish.
- NRXP’s TA Score: 5 bullish, 4 bearish.
Price Growth
ALLR (@Biotechnology) experienced а -19.45% price change this week, while NRXP (@Biotechnology) price change was +5.36% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
ALLR is expected to report earnings on Nov 13, 2026.
NRXP is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALLR and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALLR has been closely correlated with TAOX. These tickers have moved in lockstep 87% of the time. This A.I.-generated data suggests there is a high statistical probability that if ALLR jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To ALLR | 1D Price Change % | ||
|---|---|---|---|---|
| ALLR | 100% | -3.49% | ||
| TAOX - ALLR | 87% Closely correlated | -5.15% | ||
| NRXP - ALLR | 81% Closely correlated | -0.84% | ||
| ACRV - ALLR | 48% Loosely correlated | -0.63% | ||
| BCTX - ALLR | 35% Loosely correlated | -1.07% | ||
| IVVD - ALLR | 34% Loosely correlated | -3.66% | ||
More | ||||
NRXP and
Correlation & Price change
A.I.dvisor indicates that over the last year, NRXP has been closely correlated with TAOX. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To NRXP | 1D Price Change % | ||
|---|---|---|---|---|
| NRXP | 100% | -0.84% | ||
| TAOX - NRXP | 84% Closely correlated | -5.15% | ||
| ALLR - NRXP | 81% Closely correlated | -3.49% | ||
| PALI - NRXP | 74% Closely correlated | -5.04% | ||
| COYA - NRXP | 39% Loosely correlated | -5.11% | ||
| BCYC - NRXP | 35% Loosely correlated | -2.12% | ||
More | ||||